Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
13 05 2020
Historique:
received: 29 07 2019
revised: 26 11 2019
accepted: 15 04 2020
entrez: 15 5 2020
pubmed: 15 5 2020
medline: 24 6 2021
Statut: ppublish

Résumé

Identifying immune correlates of protection and mechanisms of immunity accelerates and streamlines the development of vaccines. RTS,S/AS01E, the most clinically advanced malaria vaccine, has moderate efficacy in African children. In contrast, immunization with sporozoites under antimalarial chemoprophylaxis (CPS immunization) can provide 100% sterile protection in naïve adults. We used systems biology approaches to identifying correlates of vaccine-induced immunity based on transcriptomes of peripheral blood mononuclear cells from individuals immunized with RTS,S/AS01E or chemoattenuated sporozoites stimulated with parasite antigens in vitro. Specifically, we used samples of individuals from two age cohorts and three African countries participating in an RTS,S/AS01E pediatric phase 3 trial and malaria-naïve individuals participating in a CPS trial. We identified both preimmunization and postimmunization transcriptomic signatures correlating with protection. Signatures were validated in independent children and infants from the RTS,S/AS01E phase 3 trial and individuals from an independent CPS trial with high accuracies (>70%). Transcription modules revealed interferon, NF-κB, Toll-like receptor (TLR), and monocyte-related signatures associated with protection. Preimmunization signatures suggest that priming the immune system before vaccination could potentially improve vaccine immunogenicity and efficacy. Last, signatures of protection could be useful to determine efficacy in clinical trials, accelerating vaccine candidate testing. Nevertheless, signatures should be tested more extensively across multiple cohorts and trials to demonstrate their universal predictive capacity.

Identifiants

pubmed: 32404508
pii: 12/543/eaay8924
doi: 10.1126/scitranslmed.aay8924
pii:
doi:

Substances chimiques

Antibodies, Protozoan 0
Malaria Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI095789
Pays : United States

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Gemma Moncunill (G)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain. gemma.moncunill@isglobal.org carlota.dobano@isglobal.org.
Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

Anja Scholzen (A)

Department of Medical Microbiology, Radboud University Medical Center, 6500 HB Nijmegen, Netherlands.

Maximillian Mpina (M)

Ifakara Health Institute, Bagamoyo Research and Training Centre. P.O. Box 74, Bagamoyo, Tanzania.
Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland.
University of Basel, Petersplatz 1, 4001 Basel, Switzerland.

Augusto Nhabomba (A)

Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

Aurore Bouyoukou Hounkpatin (AB)

Centre de Recherches Médicales de Lambaréné (CERMEL), BP 242 Lambaréné, Gabon.
Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, Wilhelmstraße 27, D-72074 Tübingen, Germany.

Lourdes Osaba (L)

Progenika Biopharma. A Grifols Company, S.A., 48160 Derio, Vizcaya, Spain.

Raquel Valls (R)

Anaxomics Biotech, S.L, 08008 Barcelona, Spain.

Joseph J Campo (JJ)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

Hèctor Sanz (H)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain.

Chenjerai Jairoce (C)

Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

Nana Aba Williams (NA)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain.

Erica M Pasini (EM)

Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands.

David Arteta (D)

Progenika Biopharma. A Grifols Company, S.A., 48160 Derio, Vizcaya, Spain.

Joan Maynou (J)

Progenika Biopharma. A Grifols Company, S.A., 48160 Derio, Vizcaya, Spain.

Lourdes Palacios (L)

Progenika Biopharma. A Grifols Company, S.A., 48160 Derio, Vizcaya, Spain.

Miquel Duran-Frigola (M)

Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, 08028 Barcelona, Catalonia, Spain.

John J Aponte (JJ)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain.

Clemens H M Kocken (CHM)

Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands.

Selidji Todagbe Agnandji (ST)

Centre de Recherches Médicales de Lambaréné (CERMEL), BP 242 Lambaréné, Gabon.
Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, Wilhelmstraße 27, D-72074 Tübingen, Germany.

José Manuel Mas (JM)

Anaxomics Biotech, S.L, 08008 Barcelona, Spain.

Benjamin Mordmüller (B)

Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, Wilhelmstraße 27, D-72074 Tübingen, Germany.

Claudia Daubenberger (C)

Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland.
University of Basel, Petersplatz 1, 4001 Basel, Switzerland.

Robert Sauerwein (R)

Department of Medical Microbiology, Radboud University Medical Center, 6500 HB Nijmegen, Netherlands.

Carlota Dobaño (C)

ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain. gemma.moncunill@isglobal.org carlota.dobano@isglobal.org.
Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH